Alkermes plc. ALKS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
6.24
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.5B | $241.7M | — | $480.3M | $1.8B |
| 2024 | $1.6B | $367.1M | — | $405.6M | $1.5B |
| 2023 | $1.7B | $355.8M | — | $353.3M | $1.2B |
| 2022 | $1.1B | -$158.3M | — | -$17.2M | $1.0B |
| 2021 | $1.2B | -$48.2M | — | $73.7M | $1.1B |
| 2020 | $1.0B | -$110.9M | — | $40.6M | $1.1B |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.24 (safe)
- Working capital / assets 0.557
- Retained earnings / assets -0.295
- EBIT / assets 0.102
- Equity / liabilities 2.725
Source: SEC EDGAR filings · CIK 0001520262 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.